Entellus Medical, Inc. (NASDAQ:ENTL) VP Karen E. Peterson sold 650 shares of Entellus Medical stock in a transaction on Monday, October 9th. The shares were sold at an average price of $20.17, for a total value of $13,110.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Entellus Medical, Inc. (NASDAQ:ENTL) traded up 1.39% during midday trading on Wednesday, hitting $19.75. The stock had a trading volume of 76,628 shares. Entellus Medical, Inc. has a 1-year low of $11.47 and a 1-year high of $22.63. The stock’s market cap is $501.08 million. The company has a 50-day moving average of $18.18 and a 200-day moving average of $18.18.

Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The firm had revenue of $22.10 million during the quarter, compared to the consensus estimate of $21.87 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The firm’s revenue was up 18.0% on a year-over-year basis. Equities research analysts forecast that Entellus Medical, Inc. will post ($1.61) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/entellus-medical-inc-entl-vp-sells-13110-50-in-stock.html.

Several institutional investors and hedge funds have recently made changes to their positions in ENTL. Frontier Capital Management Co. LLC lifted its stake in shares of Entellus Medical by 85.0% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock valued at $14,347,000 after acquiring an additional 397,953 shares during the last quarter. Tekla Capital Management LLC bought a new position in shares of Entellus Medical in the 2nd quarter valued at $5,655,000. Nicholas Company Inc. lifted its stake in shares of Entellus Medical by 1,052.3% in the 2nd quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock valued at $4,101,000 after acquiring an additional 226,190 shares during the last quarter. Kingdon Capital Management L.L.C. lifted its stake in shares of Entellus Medical by 79.6% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock valued at $6,215,000 after acquiring an additional 199,615 shares during the last quarter. Finally, Grandeur Peak Global Advisors LLC lifted its stake in shares of Entellus Medical by 868.1% in the 1st quarter. Grandeur Peak Global Advisors LLC now owns 212,491 shares of the medical technology company’s stock valued at $2,932,000 after acquiring an additional 190,541 shares during the last quarter. Institutional investors own 70.27% of the company’s stock.

Several research firms have recently commented on ENTL. Zacks Investment Research raised Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Monday. BidaskClub raised Entellus Medical from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 14th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $21.00 target price on shares of Entellus Medical in a research note on Tuesday, August 22nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $22.00.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.